Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 3, 2005, Pages 289-292

  Cianci, Christopher ^a   Meanwell, Nicholas ^a   Krystal, Mark ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

BMS 433771; Heptad repeats; Respiratory syncytial virus; Trimer of hairpins

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BMS 433771; CL 387626; HYBRID PROTEIN; JNJ 2408068; R 170591; RESPIRATORY SYNCYTIAL VIRUS FUSION INHIBITOR; RFI 641; SIALIDASE INHIBITOR; SP 78; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AFFINITY LABELING; AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; MEMBRANE FUSION; NONHUMAN; PROTEIN STRUCTURE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION; VIRUS INHIBITION;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; BENZIMIDAZOLES; HUMANS; MEMBRANE FUSION; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 15844371374     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh558     Document Type: Article

References (19)

1. Heikkinen, T. & Chonmaitree, T. (2003). Importance of respiratory viruses in acute otitis media. Clinical Microbiology Reviews 16, 230-41.
2. Falsey, A. R. & Walsh, E. E. (2000). Respiratory syncytial virus infection in adults. Clinical Microbiology Reviews 13, 371-84.
3. Yu, K. L., Zhang, Y., Civiello, R. L. et al. (2003). Fundamental structure-activity relationships associated with a new structural class of respiratory syncytial virus inhibitor. Bioorganic and Medicinal Chemistry Letters 13, 2141-4.
4. Yu, K. L., Zhang, Y., Civiello, R. L. et al. (2004). Respiratory syncytial virus inhibitors. Part 2: Benzimidazol-2-one derivatives. Bioorganic and Medicinal Chemistry Letters 14, 1133-7.
5. Cianci, C., Yu, K. Y., Combrink, K. et al. (2004). In vitro characterization of an orally active fusion inhibitor of respiratory syncytial virus. Antimicrobial Agents and Chemotherapy 48, 413-22.
6. Kilby, J. M., Lalezari, J. P., Eron, J. J. et al. (2003). The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous Enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Research and Human Retroviruses 19, 685-93.
7. Lambert, D. M., Barney, S., Lambert, A. L. et al. (1996). Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proceedings of the National Academy of Sciences, USA 93, 2186-91.
8. Dischino, D. D., Cianci, C. W., Civiello, R. et al. (2003). Development of a photoaffinity label for respiratory syncytial virus inhibitors. Journal of Labeled Compounds and Radiopharmaceuticals 46, 1105-16.
9. Cianci, C., Langley, D. R., Dischino, D. D. et al. (2004). Targeting a binding pocket within the trimer-of-hairpins: small molecule inhibition of viral fusion. Proceedings of the National Academy of Sciences, USA 101, 15046-51.
10. Zhao, X., Singh, M., Malashkevich, V. N. et al. (2000). Structural characterization of the human respiratory syncytial virus fusion protein core. Proceedings of the National Academy of Sciences, USA 97, 14172-7.
11. Cianci, C., Genovesi, E. V., Lamb, L. et al. (2004). Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrobial Agents and Chemotherapy 48, 2448-54.
12. Wyde, P. R., Moore-Proveda, D. K., O'Hara, B. et al. (1998). CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats. Antiviral Research 38, 31-42.
13. Huntley, C. C., Weiss, W. J., Gazumyan, A. et al. (2002). RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrobial Agents and Chemotherapy 46, 841-7.
14. Wyde, P. R., Chetty, S. N., Timmerman, P. et al. (2003). Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. Antiviral Research 60, 221-31.
15. McKimm-Breschkin, J. (2000). VP-14637 ViroPharma. Current Opinion in Investigational Drugs 1, 425-7.
16. Wilson, L., Alber, D., Carter, M. et al. (2004) Characterisation and mode of action for A-60444; a novel small molecule inhibitor of RSV. In Programs and Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract F-489 American Society for Microbiology, Washington, DC, USA.
17. Ison, M. G. & Hayden, F. G. (2001). Therapeutic options for the management of influenza. Current Opinion in Pharmacology 1 482-90.
18. Polak, M. J. (2004). Respiratory syncytial virus (RSV): overview, treatment, and prevention strategies. Newborn and Infant Nursing Reviews 14, 15-23.
19. Broughton, S. & Greenough, A. (2003). Effectiveness of drug therapies to treat or prevent respiratory syncytial virus infection-related morbidity. Expert Opinion in Pharmacotherapy 4 1801-8.